Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer - Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

开始日期2012-12-01

申办/合作机构

OncoTherapy Science, Inc.

JPRN-UMIN000005162 / Completed临床2期

Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer - Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer

开始日期2011-03-01

申办/合作机构

OncoTherapy Science, Inc.

JPRN-UMIN000002876 / Completed

Continuous administration trial of OTS11101 - Continuous administration trial of OTS11101

开始日期2009-12-01

申办/合作机构

OncoTherapy Science, Inc.

100 项与 OCV-101 相关的临床结果

登录后查看更多信息

100 项与 OCV-101 相关的转化医学

登录后查看更多信息

100 项与 OCV-101 相关的专利（医药）

登录后查看更多信息

项与 OCV-101 相关的文献（医药）

2012-03-01·Gan to kagaku ryoho. Cancer & chemotherapy

[Multidisciplinary therapy for pancreatic cancer - clinical impact for preoperative therapy and peptide vaccine therapy].

Review

作者: Tani, Masaji ; Yamaue, Hiroki

Pancreatic cancer survival is poor for those with high-grade malignancy, so multidisciplinary therapy is required for pancreatic cancer patients. Borderline resectable pancreatic cancer patients, according to the National Comprehensive Cancer Net- work(NCCN), have a high incidence of R1/2 resection, which demonstrates poor survival. It is thought that not only postoperative therapy but also preoperative therapy is essential to improve the survival of advanced pancreatic cancer patients. Preoperative chemoradiotherapy leads to R0 resection, resulting in improved survival of borderline resectable pancreatic cancer patients. Metastatic disease survival might be improved by intensive chemotherapy, and super-responder chemotherapy might be performed for resection, which means the new concept of adjuvant chemotherapy. On the other hand, antigenspecific CD8-positive CTL is generated by stimulation of peptide. Three clinical trials are on-going using OCV-101, OCV-105, and OTS-102, respectively. The development of a peptide vaccine used as a medicine is anticipated.

100 项与 OCV-101 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除性胰腺癌	临床2期	日本	OncoTherapy Science, Inc.	2011-03-01
胰腺癌	临床2期	-	Otsuka Holdings Co., Ltd.	-
实体瘤	药物发现	日本	-	-